Advanced Controlled-Release Solutions for Pharma & Biotech
Achieving precise, predictable, and scalable drug release is essential for transforming complex molecules into clinically viable therapies. Our Nanoparticle Drug Release Services leverage state-of-the-art nanotechnology platforms, advanced analytical capabilities, and specialized formulation engineering to help pharmaceutical, biotechnology, and drug-delivery companies accelerate the development of safe, effective, and commercially scalable products. Whether you are working with small molecules, poorly soluble APIs, peptides, nucleic acids (mRNA, siRNA, DNA), complex biologics, or multi-payload combinations, our scientific team delivers custom nanoparticle-based controlled-release solutions designed to meet the highest regulatory, quality, and manufacturing standards. We support companies throughout the full development lifecycle—from early feasibility and release optimization to preclinical readiness and scale-up strategy—ensuring each formulation aligns with goals and downstream manufacturing requirements.
Nanoparticles offer an unmatched ability to fine-tune pharmacokinetics and therapeutic performance. By engineering carrier systems at the nanoscale, drug developers can achieve:
Controlled Release Profile: Nanoparticles enable sustained, delayed, or programmed drug release to improve therapeutic performance and reduce dosing frequency.
Enhanced Bioavailability: Nano-sized carriers increase dissolution, permeability, and systemic absorption of poorly soluble or unstable APIs.
Targeted Drug Delivery: Surface-engineered nanoparticles direct drugs to specific tissues or cells, boosting efficacy while minimizing off-target effects.
Improved Safety & Reduced Toxicity: Encapsulation protects healthy tissues from high drug exposure and enables more favorable PK/PD profiles.
Stability & Protection of Sensitive Molecules: Nanocarriers shield peptides, proteins, and nucleic acids from degradation during circulation.
Stimuli-Responsive Release: Smart nanoparticles respond to pH, enzymes, temperature, or redox environments for precise, on-demand drug release.
High Drug-Loading Capacity: Engineered nanostructures allow efficient encapsulation of small molecules, biologics, and combination payloads.
Versatile Material Platforms: Polymeric, lipid-based, inorganic, and hybrid nanoparticles allow tailored release kinetics across diverse therapeutic modalities.
Our Nanoparticle Drug Release Capabilities combine advanced formulation science, precision engineering, and data-driven analytical expertise to support pharma and biotech organizations across the full drug-development lifecycle. We design, optimize, and characterize nanoparticle systems that provide controlled, predictable, and tunable release profiles. From early feasibility to scale-up strategy, our multidisciplinary team ensures every formulation meets stringent performance, quality, and regulatory expectations.
Our development team works across multiple nanoparticle platforms to accommodate different APIs, release profiles, and regulatory requirements. Each system provides unique advantages in terms of stability, bioavailability, manufacturing scalability, and release control. The comparison below outlines the core features and application strengths of the platforms we support.
| Nanoparticle Platform | Key Benefits | Typical Applications | Release Characteristics |
| Polymeric Nanoparticles (PLGA, PLA-PEG) | Biodegradable, tunable degradation | Oncology, peptides, biologics | Sustained & controlled release |
| Lipid Nanoparticles (LNP) | High encapsulation for nucleic acids | mRNA, siRNA, vaccines | Rapid or modulated intracellular release |
| Solid Lipid Nanoparticles (SLN) | High stability, scalable | Ophthalmic, anti-infectives | Sustained release |
| Nanostructured Lipid Carriers (NLC) | High loading capacity | Small molecules, CNS | Sustained & boosted permeability |
| Nanoemulsions / Micelles | Enhances solubility | Poorly soluble APIs | Fast or controlled release (by composition) |
| Inorganic Nanoparticles | Surface modifiable | Imaging, targeted therapy | Triggered release (pH, enzyme, heat) |
Robust analytical testing is critical to ensuring that each nanoparticle formulation meets targeted release specifications and stability requirements. We employ a full suite of physicochemical and release-testing methods to support data-driven decision-making throughout development. The table below highlights our core analytical capabilities and their relevance to nanoparticle evaluation.
| Analytical Method | Purpose | Typical Output |
| Particle size & PDI | Assess nanoparticle uniformity | DLS-based size distribution |
| Zeta potential | Surface charge evaluation | Stability prediction |
| Encapsulation efficiency | Measure loading capacity | % EE / drug loading |
| In-vitro release testing | Release kinetics profiling | Release curves, rate constants |
| Stability testing | Predict long-term behavior | Degradation & potency trends |
We begin by understanding your API, therapeutic goals, and desired release kinetics. A customized study plan is established to define the technical pathway and success criteria.
Based on your target profile, we select the most appropriate nanoparticle platform—polymeric, lipid-based, inorganic, or hybrid—to match the required release behavior. Preliminary feasibility and compatibility assessments are conducted.
Our scientists develop and refine nanoparticle formulations to achieve the desired encapsulation efficiency, stability, and controlled-release performance. Multiple design variables are iterated to ensure optimal functionality.
We perform detailed in-vitro release studies using validated or custom methods to characterize release kinetics under relevant physiological conditions. Data-driven insights guide further formulation adjustments.
Accelerated and real-time stability tests confirm formulation robustness. Parallel process development assesses scalability and manufacturability for preclinical or GMP production.
A comprehensive data package is prepared to support preclinical studies and regulatory submissions. Formulation and process knowledge is transferred seamlessly to your internal team or manufacturing partner.
Industry-Leading ExpertiseOur scientists specialize in nanomedicine, polymer chemistry, lipid engineering, and controlled-release technologies.
Flexible Engagement ModelsFrom feasibility studies to fully integrated CDMO-style support.
Fast Turnaround & Predictable TimelinesAccelerated screening and release-profiling platforms shorten development cycles.
High-Transparency CollaborationYou maintain full visibility into formulation strategy, analytical results, and decision-making.
(mRNA, siRNA, DNA)
We support a wide range of platforms including polymeric nanoparticles (PLGA, PLA-PEG, PCL), lipid nanoparticles (LNP, SLN, NLC), micelles, nanoemulsions, nanogels, and selected inorganic systems such as silica or gold nanoparticles.
Yes. We design sustained, delayed, immediate, or stimuli-responsive release profiles based on your therapeutic goals, API properties, and target product profile.
We typically require API characteristics (solubility, stability, pKa, logP), target dose, desired release kinetics, administration route, and any known formulation constraints.
Absolutely. We support biologics and genetic materials including peptides, proteins, mRNA, siRNA, DNA, and oligonucleotides through specialized nanoparticle encapsulation and stability strategies.
Our analytical package includes particle size/PDI, zeta potential, encapsulation efficiency, IVRT release profiling, stability testing, and customized assays depending on your molecule and release mechanism.
Accelerate your formulation strategy with a nanoparticle drug release solution engineered specifically for your molecule and development stage. Whether you aim to improve bioavailability, achieve long-acting release, or advance a novel therapeutic modality, our scientific team will evaluate your API, target product profile, and regulatory pathway to design a customized development plan.
We provide feasibility assessments, experimental roadmaps, and projected timelines that align with your technical objectives and operational constraints. Every proposal is built on scientific rigor, transparent communication, and a clear understanding of your therapeutic priorities. By partnering with us, you gain direct access to nanotechnology experts, formulation engineers, analytical chemists, and scale-up specialists who work collaboratively to shorten development cycles and reduce project risk. Our approach ensures that you receive actionable insights, well-defined milestones, and data-driven recommendations from day one. If you are ready to advance your program—or exploring potential release strategies for a new target—our team is here to support you with strategic guidance and practical execution. Request a tailored project proposal, sample study design, or technical consultation today and let's accelerate your next breakthrough.
